Company research
Kodiak Sciences Inc.
CIK 1468748Updated Nov 13, 2026
SecurityKOD · NASDAQ · equity
Name history
Oligasis, LLC · through Jul 28, 2009
KOD price & chart
Loading TradingView…
NASDAQ:KOD on TradingView ↗About the company
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in wet AMD, diabetic retinopathy, and retinal vein occlusion. KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.
In the news
4 Explosive Stories Enter the Investor Spotlight ↗
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares News provided by Kodiak Sciences Inc. Dec 18, 2025, 20:26 ET Share this article Share to X Share this article Share to X PALO ALTO, Calif. , ↗
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock News provided by Kodiak Sciences Inc. Dec 16, 2025, 22:55 ET Share this article Share to X Share this article Share to X PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a precommercial ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
S-3ASR filing
SCHEDULE 13D/A - filed by BAKER BROS. ADVISORS LP regarding Kodiak Sciences Inc.
Show 5 more recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 218,069,000Source | 372,669,000Source | 256,811,000Source | 256,725,000Source | 401,578,000Source | 306,006,000Source | 297,909,000Source | 434,759,000Source | 351,533,000Source | 335,578,000Source | 479,372,000Source | 666,628,000Source |
| Property, Plant and Equipment, NetUSD | 88,905,000Source | 106,688,000Source | 78,308,000Source | 93,433,000Source | 111,334,000Source | 81,512,000Source | 97,903,000Source | 115,801,000Source | 85,258,000Source | 102,222,000Source | 120,482,000Source | 56,384,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 72,038,000Source | 197,864,000Source | 125,903,000Source | 104,165,000Source | 219,225,000Source | 169,530,000Source | 138,851,000Source | 245,919,000Source | 209,862,000Source | 168,074,000Source | 285,507,000Source | 190,433,000Source |
| Assets, CurrentUSD | 75,728,000Source | 202,493,000Source | 131,358,000Source | 107,919,000Source | 224,628,000Source | 175,258,000Source | 142,685,000Source | 251,512,000Source | 214,816,000Source | 171,936,000Source | 289,309,000Source | 486,005,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,690,000Source | 4,629,000Source | 5,455,000Source | 3,754,000Source | 5,403,000Source | 5,728,000Source | 3,834,000Source | 5,593,000Source | 4,954,000Source | 3,862,000Source | 3,802,000Source | 7,072,000Source |
| Operating Lease, Right-of-Use AssetUSD | 38,577,000Source | 48,564,000Source | 32,299,000Source | 40,529,000Source | 50,576,000Source | 34,375,000Source | 42,473,000Source | 52,561,000Source | 36,606,000Source | 46,508,000Source | 54,541,000Source | 59,369,000Source |
| Other Assets, NoncurrentUSD | 8,675,000Source | 8,740,000Source | 8,662,000Source | 8,660,000Source | 8,856,000Source | 8,677,000Source | 8,664,000Source | 8,701,000Source | 8,669,000Source | 8,728,000Source | 8,716,000Source | 58,546,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 194,377,000Source | 187,299,000Source | 195,715,000Source | 186,435,000Source | 187,072,000Source | 193,905,000Source | 189,067,000Source | 193,570,000Source | 194,150,000Source | 185,290,000Source | 213,591,000Source | 230,461,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,501,969,000Source | -1,284,633,000Source | -1,682,506,000Source | -1,440,512,000Source | -1,240,687,000Source | -1,616,863,000Source | -1,386,199,000Source | -1,195,570,000Source | -1,558,705,000Source | -1,328,738,000Source | -1,152,531,000Source | -892,040,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -1,307,000Source |
| Stockholders' Equity Attributable to ParentUSD | 23,692,000Source | 185,370,000Source | 61,096,000Source | 70,290,000Source | 214,506,000Source | 112,101,000Source | 108,842,000Source | 241,189,000Source | 157,383,000Source | 150,288,000Source | 265,781,000Source | 436,167,000Source |
| Additional Paid in Capital, Common StockUSD | 1,525,656,000Source | 1,469,998,000Source | 1,743,596,000Source | 1,510,797,000Source | 1,455,188,000Source | 1,728,958,000Source | 1,495,036,000Source | 1,436,754,000Source | 1,716,082,000Source | 1,479,021,000Source | 1,418,307,000Source | 1,329,509,000Source |
| Liabilities and EquityUSD | 218,069,000Source | 372,669,000Source | 256,811,000Source | 256,725,000Source | 401,578,000Source | 306,006,000Source | 297,909,000Source | 434,759,000Source | 351,533,000Source | 335,578,000Source | 479,372,000Source | 666,628,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 42,429,000Source | 24,060,000Source | 52,770,000Source | 31,011,000Source | 21,203,000Source | 49,573,000Source | 30,876,000Source | 24,855,000Source | 45,533,000Source | 25,573,000Source | 41,729,000Source | 52,496,000Source |
| Operating Lease, Liability, CurrentUSD | 11,753,000Source | 10,196,000Source | 9,811,000Source | 11,288,000Source | 9,888,000Source | 11,660,000Source | 10,948,000Source | 9,605,000Source | 12,063,000Source | 10,628,000Source | 9,770,000Source | 9,926,000Source |
| Accounts Payable, CurrentUSD | 10,371,000Source | 3,292,000Source | 12,639,000Source | 5,057,000Source | 1,874,000Source | 11,344,000Source | 6,543,000Source | 2,485,000Source | 12,863,000Source | 3,915,000Source | 13,608,000Source | 9,130,000Source |
| Operating Lease, Liability, NoncurrentUSD | 50,448,000Source | 63,239,000Source | 42,945,000Source | 53,924,000Source | 65,869,000Source | 44,332,000Source | 56,691,000Source | 68,715,000Source | 47,117,000Source | 59,717,000Source | 71,862,000Source | 77,807,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 162,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 20,305,000Source | 10,572,000Source | 30,320,000Source | 14,666,000Source | 9,441,000Source | 26,569,000Source | 13,385,000Source | 12,765,000Source | 20,607,000Source | 11,030,000Source | 18,351,000Source | 33,440,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 12,155,000Source | 15,891,000Source | 58,863,000Source | 60,213,000Source | 88,556,000Source | 106,033,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -733,000Source | 2,606,000Source | 8,070,000Source | -9,693,000Source | 5,597,000Source | 1,660,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -40,009,000Source | -29,077,000Source | -136,008,000Source | -117,319,000Source | -154,183,000Source | -206,459,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -942,000Source | -270,000Source | -506,000Source | -755,000Source | 249,226,000Source | -336,513,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 942,000Source | 270,000Source | 506,000Source | 375,000Source | 41,350,000Source | 37,021,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 619,000Source | 124,000Source | 178,302,000Source | 501,000Source | 31,000Source | 1,895,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 13,000Source | 18,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 14,046,000Source | 14,810,000Source | 11,608,000Source | 15,641,000Source | 12,155,000Source | 15,891,000Source | 58,863,000Source | 60,213,000Source | 88,556,000Source | 106,033,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| DepreciationUSD | — | — | — | — | — | — | 4,109,000Source | 4,603,000Source | 18,328,000Source | 18,710,000Source | 18,298,000Source | 3,796,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | -1,000,000Source | 300,000Source | 100,000Source | -300,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | 0Source | 0Source | -355,000Source | 0Source | 616,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | 0Source | -2,000Source | — |
| General and Administrative ExpenseUSD | — | — | 11,876,000Source | 14,754,000Source | 10,755,000Source | 12,750,000Source | 11,230,000Source | 15,429,000Source | 52,015,000Source | 60,754,000Source | 71,023,000Source | 73,788,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 52,000Source | 20,000Source | 33,000Source | 33,000Source |
| Investment Income, InterestUSD | — | — | 917,000Source | 2,711,000Source | 1,255,000Source | 1,241,000Source | 1,641,000Source | 1,602,000Source | 4,517,000Source | 11,148,000Source | 16,733,000Source | 7,071,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -61,457,000Source | -43,946,000Source | -65,643,000Source | -54,313,000Source | -58,158,000Source | -57,461,000Source | -229,967,000Source | -176,207,000Source | -260,491,000Source | -333,823,000Source |
| Operating ExpensesUSD | — | — | 62,352,000Source | 46,632,000Source | 66,838,000Source | 55,510,000Source | 59,777,000Source | 59,073,000Source | 234,388,000Source | 186,849,000Source | 277,321,000Source | 341,379,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -22,000Source | -25,000Source | -60,000Source | -44,000Source | -22,000Source | 10,000Source | -96,000Source | -506,000Source | 110,000Source | 503,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 922,000Source | 124,000Source | 5,162,000Source | 394,000Source | 60,000Source | 1,770,000Source |
| Gain (Loss) on Disposition of Assets | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -62,352,000Source | -46,632,000Source | -66,838,000Source | -55,510,000Source | -59,777,000Source | -59,073,000Source | -234,388,000Source | -186,849,000Source | -277,321,000Source | -341,379,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -22,000Source | -25,000Source | -60,000Source | -44,000Source | -22,000Source | 10,000Source | -96,000Source | -506,000Source | 110,000Source | 503,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -229,915,000Source | -176,187,000Source | 260,432,000Source | 333,790,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 52,000Source | 20,000Source | 33,000Source | 33,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -61,457,000Source | -43,946,000Source | -65,643,000Source | -54,313,000Source | -58,158,000Source | -57,461,000Source | -229,967,000Source | -176,207,000Source | -260,491,000Source | -333,823,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.16Source | -0.84Source | -1.05Source | -1.03Source | -0.94Source | -1.09Source | -4.32Source | -3.35Source | -4.97Source | -6.39Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.16Source | -0.84Source | -1.05Source | -1.03Source | -0.94Source | -1.09Source | -4.32Source | -3.35Source | -4.97Source | -6.39Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 52,859,308Source | 52,616,183Source | 62,628,596Source | 52,779,162Source | 61,859,485Source | 52,746,318Source | 53,208,311Source | 52,583,148Source | 52,414,256Source | 52,249,620Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 52,859,308Source | 52,616,183Source | 62,628,596Source | 52,779,162Source | 61,859,485Source | 52,746,318Source | 53,208,311Source | 52,583,148Source | 52,414,256Source | 52,249,620Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 20,000Source | 33,000Source | 33,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | -1,000,000Source | 300,000Source | 100,000Source | -300,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | 0Source | 0Source | -355,000Source | 0Source | 616,000Source |
| General and Administrative ExpenseUSD | — | — | 11,876,000Source | 14,754,000Source | 10,755,000Source | 12,750,000Source | 11,230,000Source | 15,429,000Source | 52,015,000Source | 60,754,000Source | 71,023,000Source | 73,788,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -154,535,000Source | -118,783,000Source | -143,256,000Source | -163,240,000Source |
| Interest ExpenseUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 13,000Source | 18,000Source |
| Investment Income, InterestUSD | — | — | 917,000Source | 2,711,000Source | 1,255,000Source | 1,241,000Source | 1,641,000Source | 1,602,000Source | 4,517,000Source | 11,148,000Source | 16,733,000Source | 7,071,000Source |
| Operating ExpensesUSD | — | — | 62,352,000Source | 46,632,000Source | 66,838,000Source | 55,510,000Source | 59,777,000Source | 59,073,000Source | 234,388,000Source | 186,849,000Source | 277,321,000Source | 341,379,000Source |
| Research and Development ExpenseUSD | — | — | 50,476,000Source | 31,878,000Source | 56,083,000Source | 42,760,000Source | 48,547,000Source | 43,644,000Source | 182,373,000Source | 126,095,000Source | 206,298,000Source | 267,591,000Source |
Offerings
Registration 333-299552
Filing attachments
kod-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results PALO ALTO, Calif., November 12, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2026. “We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company,” said Victor Perlroth, M.D., Chief Executive O…
Read attachment ↗d143488dex43.htm · S-3ASR · 2026-10-20
Exhibit 4.3 KODIAK SCIENCES INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗d143488dex45.htm · S-3ASR · 2026-10-20
Exhibit 4.5 K ODIAK S CIENCES I NC. AND _____________, A S W ARRANT A GENT F ORM OF C OMMON S TOCK W ARRANT A GREEMENT D ATED A S O F __________ K ODIAK S CIENCES I NC. F ORM OF C OMMON S TOCK W ARRANT A GREEMENT T HIS C OMMON S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between K ODIAK S CIENCES I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trus…
Read attachment ↗d143488dex46.htm · S-3ASR · 2026-10-20
Exhibit 4.6 K ODIAK S CIENCES I NC. AND _____________, A S W ARRANT A GENT F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT D ATED A S O F __________ K ODIAK S CIENCES I NC. F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT T HIS P REFERRED S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between K ODIAK S CIENCES I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corpo…
Read attachment ↗d143488dex47.htm · S-3ASR · 2026-10-20
Exhibit 4.7 K ODIAK S CIENCES I NC. AND _____________, A S W ARRANT A GENT F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT D ATED A S O F __________ K ODIAK S CIENCES I NC. F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT T HIS D EBT S ECURITIES W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between K ODIAK S CIENCES I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corpo…
Read attachment ↗tm2626623d1_ex99-1.htm · SCHEDULE 13D/A · 2026-09-30
Exhibit 99.1 Holder Common Stock Percent of Class Outstanding ────────────────────────────────────────────────────────────────────────────────── 667, L.P. 1,669,727 2.7% Baker Brothers Life Sciences, L.P. 20,191,214 32.1% Total 21,860,941 34.…
Read attachment ↗